Loading…
Bloodstream infections in head and neck cancer patients after curative-intent radiotherapy: a population-based study from the Danish Head and Neck Cancer Group database
Background Patients with head and neck squamous cell carcinoma (HNSCC) undergoing radiotherapy (RT) or chemoradiation (CRT) may become immunocompromised. In this population-based study, we aimed to investigate the risk factors, microbiological aetiologies, prognosis and impact on early non-cancer mo...
Saved in:
Published in: | British journal of cancer 2021-08, Vol.125 (3), p.458-464 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c540t-da8504cf1bdefb9075121e3bda7f7357c31607131fb55cb32af5e4596116763b3 |
---|---|
cites | cdi_FETCH-LOGICAL-c540t-da8504cf1bdefb9075121e3bda7f7357c31607131fb55cb32af5e4596116763b3 |
container_end_page | 464 |
container_issue | 3 |
container_start_page | 458 |
container_title | British journal of cancer |
container_volume | 125 |
creator | Jensen, Kristian Hastoft Vogelius, Ivan Moser, Claus Ernst Andersen, Elo Eriksen, Jesper Grau Johansen, Jørgen Farhadi, Mohammad Andersen, Maria Overgaard, Jens Friborg, Jeppe |
description | Background
Patients with head and neck squamous cell carcinoma (HNSCC) undergoing radiotherapy (RT) or chemoradiation (CRT) may become immunocompromised. In this population-based study, we aimed to investigate the risk factors, microbiological aetiologies, prognosis and impact on early non-cancer mortality of bloodstream infections (BSIs) after RT/CRT.
Methods
Patients with HNSCC of the pharynx, larynx and oral cavity treated with curative-intent RT/CRT in Denmark between 2010 and 2017 and subsequent BSI episodes occurring within 18 months of RT/CRT initiation were identified in national registries.
Results
We included 5674 patients and observed 238 BSIs. Increasing age, stage and performance status were significantly associated with an elevated BSI risk, while sex, smoking and high-grade mucositis were not. Human papillomavirus-positive oropharyngeal cancer patients had a decreased risk.
Staphylococcus aureus
accounted for 34% of episodes occurring during the first 3 months. The 30-day post-BSI mortality rate was 26% (95% confidence interval: 19–32) and BSIs were involved in 10% of early non-cancer deaths.
Conclusion
The risk of BSI development is associated with several patient- and disease-related factors and BSIs contribute considerably to early non-cancer mortality. Empiric antibiotic treatment regimens should prioritise coverage for
S. aureus
when treating suspected systemic infection in this population. |
doi_str_mv | 10.1038/s41416-021-01430-w |
format | article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8329195</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2557304608</sourcerecordid><originalsourceid>FETCH-LOGICAL-c540t-da8504cf1bdefb9075121e3bda7f7357c31607131fb55cb32af5e4596116763b3</originalsourceid><addsrcrecordid>eNp9Uc1u1DAQthCILoUX4IAscTaM4zhOOCDRhbZIFVzgbE1sp5uyawfbabVvxGPibdoCF072zHw_M_oIecnhDQfRvk01r3nDoOIMeC2A3TwiKy5FxXhbqcdkBQCKQVfBEXmW0lUpO2jVU3IkauAK2npFfp1sQ7ApR4c7OvrBmTwGn8qXbhxait5S78wPatAbF-mEeXQ-J4pDLqWZY2lcOzb6XNo0oh1D3riI0_4dRTqFad7iQZL1mJylKc92T4cYdrTA6Ef0Y9rQ83urLwer9WJ1FsM8UYsZD9Tn5MmA2-Re3L3H5Pvpp2_rc3bx9ezz-sMFM7KGzCy2Emoz8N66oe9ASV5xJ3qLalBCKiN4A4oLPvRSml5UOEhXy67hvFGN6MUxeb_oTnO_c9aUqyJu9RTHHca9Djjqfyd-3OjLcK1bUXW8k0Xg9Z1ADD9nl7K-CnP0ZWddSakE1A20BVUtKBNDStENDw4c9CFdvaSrS7r6Nl19U0iv_t7tgXIfZwGIBZDKyF-6-Mf7P7K_AcUVtHk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2557304608</pqid></control><display><type>article</type><title>Bloodstream infections in head and neck cancer patients after curative-intent radiotherapy: a population-based study from the Danish Head and Neck Cancer Group database</title><source>Springer Nature</source><source>PubMed Central</source><creator>Jensen, Kristian Hastoft ; Vogelius, Ivan ; Moser, Claus Ernst ; Andersen, Elo ; Eriksen, Jesper Grau ; Johansen, Jørgen ; Farhadi, Mohammad ; Andersen, Maria ; Overgaard, Jens ; Friborg, Jeppe</creator><creatorcontrib>Jensen, Kristian Hastoft ; Vogelius, Ivan ; Moser, Claus Ernst ; Andersen, Elo ; Eriksen, Jesper Grau ; Johansen, Jørgen ; Farhadi, Mohammad ; Andersen, Maria ; Overgaard, Jens ; Friborg, Jeppe</creatorcontrib><description>Background
Patients with head and neck squamous cell carcinoma (HNSCC) undergoing radiotherapy (RT) or chemoradiation (CRT) may become immunocompromised. In this population-based study, we aimed to investigate the risk factors, microbiological aetiologies, prognosis and impact on early non-cancer mortality of bloodstream infections (BSIs) after RT/CRT.
Methods
Patients with HNSCC of the pharynx, larynx and oral cavity treated with curative-intent RT/CRT in Denmark between 2010 and 2017 and subsequent BSI episodes occurring within 18 months of RT/CRT initiation were identified in national registries.
Results
We included 5674 patients and observed 238 BSIs. Increasing age, stage and performance status were significantly associated with an elevated BSI risk, while sex, smoking and high-grade mucositis were not. Human papillomavirus-positive oropharyngeal cancer patients had a decreased risk.
Staphylococcus aureus
accounted for 34% of episodes occurring during the first 3 months. The 30-day post-BSI mortality rate was 26% (95% confidence interval: 19–32) and BSIs were involved in 10% of early non-cancer deaths.
Conclusion
The risk of BSI development is associated with several patient- and disease-related factors and BSIs contribute considerably to early non-cancer mortality. Empiric antibiotic treatment regimens should prioritise coverage for
S. aureus
when treating suspected systemic infection in this population.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/s41416-021-01430-w</identifier><identifier>PMID: 34017084</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/4028/67/1536 ; 692/4028/67/2324 ; Aged ; Biomedical and Life Sciences ; Biomedicine ; Cancer Research ; Chemoradiotherapy ; Chemoradiotherapy - adverse effects ; Databases, Factual ; Denmark - epidemiology ; Disseminated infection ; Drug Resistance ; Epidemiology ; Female ; Head & neck cancer ; Head and Neck Neoplasms - drug therapy ; Head and Neck Neoplasms - radiotherapy ; Head and Neck Neoplasms - virology ; Human papillomavirus ; Humans ; Larynx ; Male ; Middle Aged ; Molecular Medicine ; Mortality ; Mucositis ; Oncology ; Oral cavity ; Oropharyngeal cancer ; Papillomavirus Infections - epidemiology ; Patients ; Pharynx ; Population studies ; Population-based studies ; Prognosis ; Radiation therapy ; Radiotherapy - adverse effects ; Registries ; Risk Factors ; Sepsis - epidemiology ; Sepsis - microbiology ; Squamous cell carcinoma ; Squamous Cell Carcinoma of Head and Neck - drug therapy ; Squamous Cell Carcinoma of Head and Neck - radiotherapy ; Squamous Cell Carcinoma of Head and Neck - virology ; Staphylococcus aureus ; Staphylococcus aureus - classification ; Staphylococcus aureus - isolation & purification ; Survival Analysis ; Throat cancer</subject><ispartof>British journal of cancer, 2021-08, Vol.125 (3), p.458-464</ispartof><rights>The Author(s), under exclusive licence to Springer Nature Limited 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer Nature Limited.</rights><rights>The Author(s), under exclusive licence to Springer Nature Limited 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c540t-da8504cf1bdefb9075121e3bda7f7357c31607131fb55cb32af5e4596116763b3</citedby><cites>FETCH-LOGICAL-c540t-da8504cf1bdefb9075121e3bda7f7357c31607131fb55cb32af5e4596116763b3</cites><orcidid>0000-0002-0814-8179</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329195/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8329195/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34017084$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jensen, Kristian Hastoft</creatorcontrib><creatorcontrib>Vogelius, Ivan</creatorcontrib><creatorcontrib>Moser, Claus Ernst</creatorcontrib><creatorcontrib>Andersen, Elo</creatorcontrib><creatorcontrib>Eriksen, Jesper Grau</creatorcontrib><creatorcontrib>Johansen, Jørgen</creatorcontrib><creatorcontrib>Farhadi, Mohammad</creatorcontrib><creatorcontrib>Andersen, Maria</creatorcontrib><creatorcontrib>Overgaard, Jens</creatorcontrib><creatorcontrib>Friborg, Jeppe</creatorcontrib><title>Bloodstream infections in head and neck cancer patients after curative-intent radiotherapy: a population-based study from the Danish Head and Neck Cancer Group database</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Background
Patients with head and neck squamous cell carcinoma (HNSCC) undergoing radiotherapy (RT) or chemoradiation (CRT) may become immunocompromised. In this population-based study, we aimed to investigate the risk factors, microbiological aetiologies, prognosis and impact on early non-cancer mortality of bloodstream infections (BSIs) after RT/CRT.
Methods
Patients with HNSCC of the pharynx, larynx and oral cavity treated with curative-intent RT/CRT in Denmark between 2010 and 2017 and subsequent BSI episodes occurring within 18 months of RT/CRT initiation were identified in national registries.
Results
We included 5674 patients and observed 238 BSIs. Increasing age, stage and performance status were significantly associated with an elevated BSI risk, while sex, smoking and high-grade mucositis were not. Human papillomavirus-positive oropharyngeal cancer patients had a decreased risk.
Staphylococcus aureus
accounted for 34% of episodes occurring during the first 3 months. The 30-day post-BSI mortality rate was 26% (95% confidence interval: 19–32) and BSIs were involved in 10% of early non-cancer deaths.
Conclusion
The risk of BSI development is associated with several patient- and disease-related factors and BSIs contribute considerably to early non-cancer mortality. Empiric antibiotic treatment regimens should prioritise coverage for
S. aureus
when treating suspected systemic infection in this population.</description><subject>692/4028/67/1536</subject><subject>692/4028/67/2324</subject><subject>Aged</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>Chemoradiotherapy</subject><subject>Chemoradiotherapy - adverse effects</subject><subject>Databases, Factual</subject><subject>Denmark - epidemiology</subject><subject>Disseminated infection</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Head & neck cancer</subject><subject>Head and Neck Neoplasms - drug therapy</subject><subject>Head and Neck Neoplasms - radiotherapy</subject><subject>Head and Neck Neoplasms - virology</subject><subject>Human papillomavirus</subject><subject>Humans</subject><subject>Larynx</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Mortality</subject><subject>Mucositis</subject><subject>Oncology</subject><subject>Oral cavity</subject><subject>Oropharyngeal cancer</subject><subject>Papillomavirus Infections - epidemiology</subject><subject>Patients</subject><subject>Pharynx</subject><subject>Population studies</subject><subject>Population-based studies</subject><subject>Prognosis</subject><subject>Radiation therapy</subject><subject>Radiotherapy - adverse effects</subject><subject>Registries</subject><subject>Risk Factors</subject><subject>Sepsis - epidemiology</subject><subject>Sepsis - microbiology</subject><subject>Squamous cell carcinoma</subject><subject>Squamous Cell Carcinoma of Head and Neck - drug therapy</subject><subject>Squamous Cell Carcinoma of Head and Neck - radiotherapy</subject><subject>Squamous Cell Carcinoma of Head and Neck - virology</subject><subject>Staphylococcus aureus</subject><subject>Staphylococcus aureus - classification</subject><subject>Staphylococcus aureus - isolation & purification</subject><subject>Survival Analysis</subject><subject>Throat cancer</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9Uc1u1DAQthCILoUX4IAscTaM4zhOOCDRhbZIFVzgbE1sp5uyawfbabVvxGPibdoCF072zHw_M_oIecnhDQfRvk01r3nDoOIMeC2A3TwiKy5FxXhbqcdkBQCKQVfBEXmW0lUpO2jVU3IkauAK2npFfp1sQ7ApR4c7OvrBmTwGn8qXbhxait5S78wPatAbF-mEeXQ-J4pDLqWZY2lcOzb6XNo0oh1D3riI0_4dRTqFad7iQZL1mJylKc92T4cYdrTA6Ef0Y9rQ83urLwer9WJ1FsM8UYsZD9Tn5MmA2-Re3L3H5Pvpp2_rc3bx9ezz-sMFM7KGzCy2Emoz8N66oe9ASV5xJ3qLalBCKiN4A4oLPvRSml5UOEhXy67hvFGN6MUxeb_oTnO_c9aUqyJu9RTHHca9Djjqfyd-3OjLcK1bUXW8k0Xg9Z1ADD9nl7K-CnP0ZWddSakE1A20BVUtKBNDStENDw4c9CFdvaSrS7r6Nl19U0iv_t7tgXIfZwGIBZDKyF-6-Mf7P7K_AcUVtHk</recordid><startdate>20210803</startdate><enddate>20210803</enddate><creator>Jensen, Kristian Hastoft</creator><creator>Vogelius, Ivan</creator><creator>Moser, Claus Ernst</creator><creator>Andersen, Elo</creator><creator>Eriksen, Jesper Grau</creator><creator>Johansen, Jørgen</creator><creator>Farhadi, Mohammad</creator><creator>Andersen, Maria</creator><creator>Overgaard, Jens</creator><creator>Friborg, Jeppe</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-0814-8179</orcidid></search><sort><creationdate>20210803</creationdate><title>Bloodstream infections in head and neck cancer patients after curative-intent radiotherapy: a population-based study from the Danish Head and Neck Cancer Group database</title><author>Jensen, Kristian Hastoft ; Vogelius, Ivan ; Moser, Claus Ernst ; Andersen, Elo ; Eriksen, Jesper Grau ; Johansen, Jørgen ; Farhadi, Mohammad ; Andersen, Maria ; Overgaard, Jens ; Friborg, Jeppe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c540t-da8504cf1bdefb9075121e3bda7f7357c31607131fb55cb32af5e4596116763b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>692/4028/67/1536</topic><topic>692/4028/67/2324</topic><topic>Aged</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>Chemoradiotherapy</topic><topic>Chemoradiotherapy - adverse effects</topic><topic>Databases, Factual</topic><topic>Denmark - epidemiology</topic><topic>Disseminated infection</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Head & neck cancer</topic><topic>Head and Neck Neoplasms - drug therapy</topic><topic>Head and Neck Neoplasms - radiotherapy</topic><topic>Head and Neck Neoplasms - virology</topic><topic>Human papillomavirus</topic><topic>Humans</topic><topic>Larynx</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Mortality</topic><topic>Mucositis</topic><topic>Oncology</topic><topic>Oral cavity</topic><topic>Oropharyngeal cancer</topic><topic>Papillomavirus Infections - epidemiology</topic><topic>Patients</topic><topic>Pharynx</topic><topic>Population studies</topic><topic>Population-based studies</topic><topic>Prognosis</topic><topic>Radiation therapy</topic><topic>Radiotherapy - adverse effects</topic><topic>Registries</topic><topic>Risk Factors</topic><topic>Sepsis - epidemiology</topic><topic>Sepsis - microbiology</topic><topic>Squamous cell carcinoma</topic><topic>Squamous Cell Carcinoma of Head and Neck - drug therapy</topic><topic>Squamous Cell Carcinoma of Head and Neck - radiotherapy</topic><topic>Squamous Cell Carcinoma of Head and Neck - virology</topic><topic>Staphylococcus aureus</topic><topic>Staphylococcus aureus - classification</topic><topic>Staphylococcus aureus - isolation & purification</topic><topic>Survival Analysis</topic><topic>Throat cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jensen, Kristian Hastoft</creatorcontrib><creatorcontrib>Vogelius, Ivan</creatorcontrib><creatorcontrib>Moser, Claus Ernst</creatorcontrib><creatorcontrib>Andersen, Elo</creatorcontrib><creatorcontrib>Eriksen, Jesper Grau</creatorcontrib><creatorcontrib>Johansen, Jørgen</creatorcontrib><creatorcontrib>Farhadi, Mohammad</creatorcontrib><creatorcontrib>Andersen, Maria</creatorcontrib><creatorcontrib>Overgaard, Jens</creatorcontrib><creatorcontrib>Friborg, Jeppe</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Biological Science Journals</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jensen, Kristian Hastoft</au><au>Vogelius, Ivan</au><au>Moser, Claus Ernst</au><au>Andersen, Elo</au><au>Eriksen, Jesper Grau</au><au>Johansen, Jørgen</au><au>Farhadi, Mohammad</au><au>Andersen, Maria</au><au>Overgaard, Jens</au><au>Friborg, Jeppe</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Bloodstream infections in head and neck cancer patients after curative-intent radiotherapy: a population-based study from the Danish Head and Neck Cancer Group database</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2021-08-03</date><risdate>2021</risdate><volume>125</volume><issue>3</issue><spage>458</spage><epage>464</epage><pages>458-464</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><abstract>Background
Patients with head and neck squamous cell carcinoma (HNSCC) undergoing radiotherapy (RT) or chemoradiation (CRT) may become immunocompromised. In this population-based study, we aimed to investigate the risk factors, microbiological aetiologies, prognosis and impact on early non-cancer mortality of bloodstream infections (BSIs) after RT/CRT.
Methods
Patients with HNSCC of the pharynx, larynx and oral cavity treated with curative-intent RT/CRT in Denmark between 2010 and 2017 and subsequent BSI episodes occurring within 18 months of RT/CRT initiation were identified in national registries.
Results
We included 5674 patients and observed 238 BSIs. Increasing age, stage and performance status were significantly associated with an elevated BSI risk, while sex, smoking and high-grade mucositis were not. Human papillomavirus-positive oropharyngeal cancer patients had a decreased risk.
Staphylococcus aureus
accounted for 34% of episodes occurring during the first 3 months. The 30-day post-BSI mortality rate was 26% (95% confidence interval: 19–32) and BSIs were involved in 10% of early non-cancer deaths.
Conclusion
The risk of BSI development is associated with several patient- and disease-related factors and BSIs contribute considerably to early non-cancer mortality. Empiric antibiotic treatment regimens should prioritise coverage for
S. aureus
when treating suspected systemic infection in this population.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>34017084</pmid><doi>10.1038/s41416-021-01430-w</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-0814-8179</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0007-0920 |
ispartof | British journal of cancer, 2021-08, Vol.125 (3), p.458-464 |
issn | 0007-0920 1532-1827 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8329195 |
source | Springer Nature; PubMed Central |
subjects | 692/4028/67/1536 692/4028/67/2324 Aged Biomedical and Life Sciences Biomedicine Cancer Research Chemoradiotherapy Chemoradiotherapy - adverse effects Databases, Factual Denmark - epidemiology Disseminated infection Drug Resistance Epidemiology Female Head & neck cancer Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - radiotherapy Head and Neck Neoplasms - virology Human papillomavirus Humans Larynx Male Middle Aged Molecular Medicine Mortality Mucositis Oncology Oral cavity Oropharyngeal cancer Papillomavirus Infections - epidemiology Patients Pharynx Population studies Population-based studies Prognosis Radiation therapy Radiotherapy - adverse effects Registries Risk Factors Sepsis - epidemiology Sepsis - microbiology Squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck - drug therapy Squamous Cell Carcinoma of Head and Neck - radiotherapy Squamous Cell Carcinoma of Head and Neck - virology Staphylococcus aureus Staphylococcus aureus - classification Staphylococcus aureus - isolation & purification Survival Analysis Throat cancer |
title | Bloodstream infections in head and neck cancer patients after curative-intent radiotherapy: a population-based study from the Danish Head and Neck Cancer Group database |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T22%3A29%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Bloodstream%20infections%20in%20head%20and%20neck%20cancer%20patients%20after%20curative-intent%20radiotherapy:%20a%20population-based%20study%20from%20the%20Danish%20Head%20and%20Neck%20Cancer%20Group%20database&rft.jtitle=British%20journal%20of%20cancer&rft.au=Jensen,%20Kristian%20Hastoft&rft.date=2021-08-03&rft.volume=125&rft.issue=3&rft.spage=458&rft.epage=464&rft.pages=458-464&rft.issn=0007-0920&rft.eissn=1532-1827&rft_id=info:doi/10.1038/s41416-021-01430-w&rft_dat=%3Cproquest_pubme%3E2557304608%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c540t-da8504cf1bdefb9075121e3bda7f7357c31607131fb55cb32af5e4596116763b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2557304608&rft_id=info:pmid/34017084&rfr_iscdi=true |